Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Mesothelioma: HELP
Articles from Thailand
Based on 5 articles published since 2008
||||

These are the 5 published articles about Mesothelioma that originated from Thailand during 2008-2019.
 
+ Citations + Abstracts
1 Review Progress in the Management of Malignant Pleural Mesothelioma in 2017. 2018

McCambridge, Amanda J / Napolitano, Andrea / Mansfield, Aaron S / Fennell, Dean A / Sekido, Yoshitaka / Nowak, Anna K / Reungwetwattana, Thanyanan / Mao, Weimin / Pass, Harvey I / Carbone, Michele / Yang, Haining / Peikert, Tobias. ·Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota. · University of Hawaii Cancer Center, Honolulu, Hawaii; Medical Oncology Department, Campus Bio-Medico, University of Rome, Rome, Italy. · Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota. · Department of Genetics and Genome Biology, University of Leicester and University Hospitals of Leicester, United Kingdom. · Division of Molecular Oncology, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya, Japan. · Medical School, University of Western Australia, Perth, Australia; National Center for Asbestos Related Diseases, University of Western Australia, Perth, Australia. · Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. · Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China; Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology of Zhejiang Province, Hangzhou, People's Republic of China. · Department of Cardiothoracic Surgery, New York University, Langone Medical Center, New York, New York. · University of Hawaii Cancer Center, Honolulu, Hawaii. · Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: Peikert.Tobias@mayo.edu. ·J Thorac Oncol · Pubmed #29524617.

ABSTRACT: Malignant pleural mesothelioma (MPM) is an uncommon, almost universally fatal, asbestos-induced malignancy. New and effective strategies for diagnosis, prognostication, and treatment are urgently needed. Herein we review the advances in MPM achieved in 2017. Whereas recent epidemiological data demonstrated that the incidence of MPM-related death continued to increase in United States between 2009 and 2015, new insight into the molecular pathogenesis and the immunological tumor microenvironment of MPM, for example, regarding the role of BRCA1 associated protein 1 and the expression programmed death receptor ligand 1, are highlighting new potential therapeutic strategies. Furthermore, there continues to be an ever-expanding number of clinical studies investigating systemic therapies for MPM. These trials are primarily focused on immunotherapy using immune checkpoint inhibitors alone or in combination with other immunotherapies and nonimmunotherapies. In addition, other promising targeted therapies, including pegylated adenosine deiminase (ADI-PEG20), which focuses on argininosuccinate synthase 1-deficient tumors, and tazemetostat, an enhancer of zeste 2 polycomb repressive complex 2 subunit inhibitor of BRCA1 associated protein 1 gene (BAP1)-deficient tumors, are currently being explored.

2 Review Asbestos-related diseases in Thailand and review literature. 2012

Subhannachart, Ponglada / Dumavibhat, Narongpon / Siriruttanapruk, Somkiat. ·Department of Radiology, Central Chest Institute of Thailand, Nonthaburi, Thailand. ·J Med Assoc Thai · Pubmed #23130478.

ABSTRACT: Asbestos is a harmful substance that can cause both malignancy and non-malignancy in humans. Although it has been used in Thailand for several years, few cases of asbestos-related diseases were reported. Concerning about high consumption and long exposure of asbestos in the country, the incurable but preventable diseases caused by asbestos will be the health problem in the near future. The authors presented 2 cases with asbestos-related diseases, one diagnosed as malignant mesothelioma and the other as asbestosis.

3 Article Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. 2017

Odgerel, Chimed-Ochir / Takahashi, Ken / Sorahan, Tom / Driscoll, Tim / Fitzmaurice, Christina / Yoko-O, Makoto / Sawanyawisuth, Kittisak / Furuya, Sugio / Tanaka, Fumihiro / Horie, Seichi / Zandwijk, Nico van / Takala, Jukka. ·Department of Environmental Epidemiology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan. · Asbestos Diseases Research Institute, Concord Clinical School, University of Sydney, Sydney, Australia. · Institute of Applied Health Research, University of Birmingham, Birmingham, UK. · School of Public Health, University of Sydney, Sydney, Australia. · Department of Medicine, Division of Hematology, Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. · Department of Medicine, Faculty of Medicine, Sleep Apnea Research Group, Khon Kaen University, Khon Kaen, Thailand. · Japan Occupational Safety and Health Resource Center, Tokyo, Japan. · Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan. · Department of Health Policy and Management, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan. · Workplace Safety and Health Institute, Ministry of Manpower, Singapore, Singapore. ·Occup Environ Med · Pubmed #28866609.

ABSTRACT: BACKGROUND: Mesothelioma is increasingly recognised as a global health issue and the assessment of its global burden is warranted. OBJECTIVES: To descriptively analyse national mortality data and to use reported and estimated data to calculate the global burden of mesothelioma deaths. METHODS: For the study period of 1994 to 2014, we grouped 230 countries into 59 countries with quality mesothelioma mortality data suitable to be used for reference rates, 45 countries with poor quality data and 126 countries with no data, based on the availability of data in the WHO Mortality Database. To estimate global deaths, we extrapolated the gender-specific and age-specific mortality rates of the countries with quality data to all other countries. RESULTS: The global numbers and rates of mesothelioma deaths have increased over time. The 59 countries with quality data recorded 15 011 mesothelioma deaths per year over the 3 most recent years with available data (equivalent to 9.9 deaths per million per year). From these reference data, we extrapolated the global mesothelioma deaths to be 38 400 per year, based on extrapolations for asbestos use. CONCLUSIONS: Although the validity of our extrapolation method depends on the adequate identification of quality mesothelioma data and appropriate adjustment for other variables, our estimates can be updated, refined and verified because they are based on commonly accessible data and are derived using a straightforward algorithm. Our estimates are within the range of previously reported values but higher than the most recently reported values.

4 Article Anaplastic lymphoma kinase (ALK) translocation in paediatric malignant peritoneal mesothelioma: a case report of novel ALK-related tumour spectrum. 2016

Loharamtaweethong, Kongsak / Puripat, Napaporn / Aoonjai, Nadda / Sutepvarnon, Apisada / Bandidwattanawong, Chanyoot. ·Department of Anatomical Pathology, Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand. · Department of Medical Services, Electron Microscopy Laboratory, Institute of Pathology, Ministry of Public Health, Bangkok, Thailand. · Department of Medical Oncology, Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand. ·Histopathology · Pubmed #26179668.

ABSTRACT: AIMS: To report a case of paediatric malignant peritoneal mesothelioma (MPM) with evidence of anaplastic lymphoma kinase (ALK) translocation. METHODS AND RESULTS: We describe a 10-year-old girl who presented with abdominal pain and progressive abdominal distension. She had no history of asbestos exposure. Histopathological, immunohistochemical and ultrastructural analyses were performed and showed a biphasic malignant mesothelioma. In addition, we also studied on a selected set of immunomarkers which may be the potential therapeutic molecular targets including ALK, c-kit (CD117), epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 (HER2)/neu, as well as corresponding molecular analysis. Consequently, we identified ALK expression by immunohistochemistry, together with evidence of ALK translocation by fluorescent in-situ hybridization (FISH) analysis. CONCLUSIONS: Paediatric MPM is associated with ALK translocation in our case. The results may open up a new avenue for the study of molecular genesis of paediatric malignant mesothelioma in the future and help to determine whether patients MMs with ALK translocation would benefit from ALK inhibitor treatment.

5 Article Huge peritoneal malignant mesothelioma mimicking primary ovarian carcinoma. 2013

Tangjitgamol, Siriwan / Warnnissorn, Malee / Attakettaworn, Kwananong / Puripat, Napaporn. ·Department of Obstetrics and Gynecology, Faculty of Medicine, Vajira Hospital, University of Bangkok Metropolis, Bangkok, Thailand. siriwanonco@yahoo.com ·J Med Assoc Thai · Pubmed #23720986.

ABSTRACT: Peritoneal malignant mesothelioma (PMM) is less commonly found in female than male. The most important differential diagnosis of PMM in female patient is primary ovarian carcinoma because of their similar symptoms e.g. dyspepsia, abdominal discomfort from ascites, palpable abdominal mass, etc. However common clinical presentation of PMM is diffuse spread of peritoneal lesions without dominating tumor mass while primary ovarian tumor usually presents with large pelvic mass and smaller exta-ovarian metastatic lesions. The surgeon may make a provisional intraoperative diagnosis of PMM if both ovaries are clearly identified Unfortunately, both conditions frequently elicit fibrosis and adhesion that the exact location or the origin of tumor cannot be clearly stated. Histopathologic diagnosis of PMM is also difficult because it has three patterns of histopathology as biphasic tumors composed of epithelial and sarcomatous components or it may be monophasic of either type. When only the epithelial component is found, serous ovarian carcinoma is the important differential diagnosis while the biphasic mesothelioma must be differentiated from malignant mesodermal mixed tumor or carcinosarcoma of the ovary. The pathologist generally requires immunohistochemical study to achieve a correct diagnosis. The clinical feature and detailed histopathologic findings of the patient with PMM will be discussed